Top Suppliers:I want be here



88191-84-8

88191-84-8 structure
88191-84-8 structure

Name Z-Val-Phe-H
Synonyms CARBOBEZOXY-VALINYL-PHENYLALANINALZ-VAL-PHE-CHO
MFCD00798796
Carbamic acid, N-[(1S)-1-[[[(1S)-1-formyl-2-phenylethyl]amino]carbonyl]-2-methylpropyl]-, phenylmethyl ester
Carbamic acid, N-[(1S)-1-formyl-2-phenylethyl]-, phenylmethyl ester
N-benzyloxycarbonyl-(S)-valinylphenylalaninal
benzyl [(2S)-1-oxo-3-phenylpropan-2-yl]carbamate
Benzyl [(2S)-3-methyl-1-oxo-1-{[(2S)-1-oxo-3-phenylpropan-2-yl]amino}butan-2-yl]carbamate
Z-Val-Phe-H
Z-VAL-PHE-CHO
(S)-(-)-2-(Benzylcarbonylamino)-3-phenylpropanal
Z-L-Val-L-Phe-OH
Benzyl [(2S)-1-oxo-3-phenyl-2-propanyl]carbamate
CARBOBENZOXY-VALINYL-PHENYLALANINAL
CALPAIN INHIBITOR III
Benzyl [(2S)-3-methyl-1-oxo-1-{[(2S)-1-oxo-3-phenyl-2-propanyl]amino}-2-butanyl]carbamate
Cbz-L-Val-L-Phe-OH
Z-VAL-PHE-ALDEHYDE
MDL 28170
MDL-28170
Description cysteine protease inhibitor of calpain that rapidly penetrates the blood-brain barrier following systemic administration[1][2]. MDL-28170 also block γ-secretase[4].
Related Catalog
Target

Calpain[1].

In Vitro MDL-28170 significantly and time-dependently improves the recovery of synaptic responses in hippocampal slices following prolonged, moderate hypoxia without hypoxic depolarization[1]. MDL-28170 dose-dependently inhibits brain cysteine proteinase activity (in vitro Ki= 0.01 μM)[2].
In Vivo Treatment with MDL-28170 (50 mg/kg, i.p.) completely prevents the striatal damage in four animals in each of the two treatment groups. The numbers of necrotic neurons are reduced by 85% and 68% in animals in which MDL-28170 injections are initiated at 0.5 and 3 h of recirculation, respectively[2]. MDL-28170 (30 mg/kg, i.p.) reduces the functional and structural deterioration of corpus callosum following fluid percussion injury[3]. MDL-28170 (10 mg/kg, i.p.) significantly improves nerve function parameters in diabetic rats. MDL-28170 (3 and 10 mg/kg, i.p.) improves nociceptive behavior in diabetic rats[5].
References

[1]. Chen ZF, et al. Neuronal recovery after moderate hypoxia is improved by the calpain inhibitor MDL28170. Brain Res. 1997 Sep 19;769(1):188-92.

[2]. Li PA, et al. Postischemic treatment with calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia. Neurosci Lett. 1998 May 8;247(1):17-20.

[3]. Ai J, et al. Calpain inhibitor MDL-28170 reduces the functional and structural deterioration of corpus callosum following fluid percussion injury. J Neurotrauma. 2007 Jun;24(6):960-78.

[4]. De Strooper B, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999 Apr 8;398(6727):518-22.

[5]. Kharatmal SB, et al. Calpain inhibitor, MDL 28170 confer electrophysiological, nociceptive and biochemical improvement in diabetic neuropathy. Neuropharmacology. 2015 Oct;97:113-21.

Density 1.2±0.1 g/cm3
Boiling Point 450.4±45.0 °C at 760 mmHg
Molecular Formula C22H26N2O4
Molecular Weight 382.45
Flash Point 226.2±28.7 °C
PSA 84.50000
LogP 3.77
Vapour Pressure 0.0±1.1 mmHg at 25°C
Index of Refraction 1.571
Storage condition 2-8℃
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Safety Phrases 22-24/25
RIDADR NONH for all modes of transport